Somerville, MANCT07501455Now EnrollingIRB Ready

Microbiome Clinical Trial in Somerville, MA

Access cutting-edge microbiome treatment through this clinical trial at a research site in Somerville. Study-provided care at no cost to qualified participants.

Sponsored by Kenvue Brands LLC

Quick Self-Assessment

See if you qualify for this Somerville location

Preparing your pre-screening questions…

Expert Care in Somerville

Access microbiome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related microbiome treatment provided free

Apply for This Somerville Location

Check if you qualify for this microbiome clinical trial in Somerville, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Somerville

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Somerville site if eligible
  4. 4Begin participation

About This Microbiome Study in Somerville

This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to assess oral tolerance after 4 weeks of twice daily use of differing oral hygiene regimens including mouthwash compared to a control group. A follow-up assessment will be completed 2 weeks after cessation of treatments.

Sponsor: Kenvue Brands LLC

Who Can Participate

Inclusion Criteria

2\. Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of gross oral neglect). 3\. Mean Modified Gingival Index (MGI) is greater than or equal to 2.00 at screening visit and reconfirmed at baseline visit. 4\. Bleeding upon probing (BOP) is greater than or equal to 30% at the screening visit. 5\. Diagnosis of gingivitis (confirmed by MGI and BOP) at the screening visit and reconfirmed at the baseline visit. 6\. Able to read and understand English. 7. Subject has signed the written informed consent (ICD) and indicated their agreement with the terms of the study and the study procedures listed and photograph release including the Health Insurance Portability and Accountability Act (HIPAA) disclosure prior to any study-related procedures. 8\. Generally, in good overall health based on the medical history reported by the subject. 9\. Has at least 18 natural teeth (not counting 3rd molars) with scorable facial and lingual surfaces. 10\. Willingness to use the assigned products according to instructions, availability for appointments, agreement to follow the subject responsibilities and likelihood of completing the clinical trial

Exclusion Criteria

Significant oral soft tissue pathology or active dental caries, based on the dentist's visual examination and at the discretion of the Investigator.
History of significant adverse reactions, including sensitivity or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses, and red food dye.
Periodontitis, as determined by more than 2 sites with a probing depth greater than 4mm.
Regular consumption of probiotics supplements within one week prior to screening. Subjects can be rescreened if they fulfill this criterion.
Dental prophylaxis within 4 weeks prior to screening. Subjects can be rescreened if they fulfill this criterion.
Subjects who wear orthodontic bands, fixed retainers, removable orthodontic appliances, clear aligners or night guards or subjects who have had significant (based on the examiner or PI's oral exam) cosmetic restorations.
History of medical conditions requiring prophylactic antibiotic coverage prior to dental procedures.
Self-reported tobacco, cannabis, smokeless tobacco use, including snuff, chewing tobacco, vaping, and e-cigarette usage.
Suspected alcohol or substance abuse.
Significant unstable or uncontrolled medical condition which may interfere with a subject's participation in the study, at the discretion of the Investigator, including a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.
Has self-reported Type 1 or Type 2 diabetes or is on an anti-diabetic medication (i.e., metformin, insulin, Glucophage, etc.)
Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
Non-steroidal anti-inflammatory drugs within 5 days before Visit 1 (81mg of aspirin is allowed).\
Use of Immunosuppressive, or steroidal drugs therapy during the study or within 2 months before Visit 2. \
Intermittent use (\<3 times per week) of certain anti-inflammatory medications is acceptable at the discretion of the investigator. Use of anticoagulant therapy within 1 month of screening visit or during the study.
Use of systemic antibiotics within 1 month of screening visit and during the entire study.
Is self-reported to be pregnant, in lactation, planning to become pregnant during the study, or positive pregnancy urine tests (females of child-bearing potential only):
For females: Postmenopausal state (i.e., at least 1 year without menses without an alternative medical condition prior to the first study IP administration) or premenopausal/perimenopausal state with an effective means of contraception.
Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the clinical trial. Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include:
Double barrier method (condoms, diaphragm or cervical cap with spermicide)
Hormonal prescription contraceptives (i.e., oral, injectable, implanted, patch or vaginal ring hormone therapy)
Intrauterine device (IUD)
Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal ligation, hysterectomy and/or bilateral oophorectomy)
For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study and for 30 days thereafter.
Participation in any clinical trial within 30 days of the Screening visit.
Subjects who were previously randomized into one of the study products as part of this study.
Subjects who are related to the people who are involved directly or indirectly with the conduct of this study (i.e., principal Investigator, sub-investigators, study coordinators, other site personnel, employees of Kenvue, contractors of Kenvue, and the families of each).
Subjects within the same household as other subjects enrolled in the study at the same time.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Somerville?

Yes, this clinical trial (NCT07501455) has an active research site in Somerville, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Microbiome Treatment Options in Somerville, MA

If you're searching for microbiome treatment options in Somerville, MA, this clinical trial (NCT07501455) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Somerville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced microbiome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all microbiome clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Somerville, MA

See all heart attack clinical trials recruiting in Somerville — not just this study.

Browse Heart Attack Trials in Somerville →

Ready to Join in Somerville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Somerville, MA